



## PRESS RELEASE

### **Profil Institute to Present at the European Association for the Study of Diabetes Annual Meeting**

SAN DIEGO, September 15, 2010 – Profil™ Institute for Clinical Research, Inc. will present key clinical and experimental diabetes and insulin-related research at the European Association of the Study of Diabetes (EASD) 46<sup>th</sup> Annual Meeting being held September 20 – 24 in Stockholm, Sweden. Profil Institute's presence as a contributor of scientific presentations emphasizes the company's position as a specialized contract research institute optimizing early phase diabetes, obesity and cardiometabolic drug development.

#### **Profil Institute's Oral Presentation**

- **Improved Glycaemic Variability in Type 1 Diabetes Mellitus and Type 2 Diabetes Mellitus Patients by Coinjection of Prandial Insulin Analogue with Human Hyaluronidase**

Drs. Marcus Hompesch, Douglas Muchmore, Linda Morrow, Elizabeth Ludington, and Daniel Vaughn

Tuesday, September 21, 10:45am - 12:15pm

Session: OP 01 Novel Formulations and Delivery of Insulin, Nobel Hall

#### **Profil Institute's Poster Presentations**

- **Poster #876: Canagliflozin, A Novel Inhibitor of Sodium Glucose Co-Transporter 2, Improved Glucose Control in Subjects with Type 2 Diabetes: Results of a Phase 1b Study**  
Tuesday, September 21, 12:30pm – 1:30pm, Poster Event A  
P.L. Rothenberg, D. Devineni, A. Ghosh, D. Polidori, M. Hompesch, S. Arnolds, L. Morrow, H. Spitzer, J. Blake, D. Wexler, Y. Tan, K. Smulders, K. Demarest, and S. Sha, USA, Germany
- **Poster #964: Comparative Pharmacokinetics and Pharmacodynamics of High-Dose Human Regular U-500 Insulin Versus Human Regular U-100 Insulin in Healthy Obese Subjects**  
Thursday, September 23, 12:30pm – 1:30pm, Poster Event E  
H. Linnebjerg, A. de la Peña, L. Morrow, H.H. Jiang, K. Win, L.L. Wolka, M. Hompesch, M. Riddle, and J.A. Jackson
- **Poster #965: More Rapid Onset and Shorter Duration of Insulin Exposure and Action for Three Rapid Insulin Analogs Coinjected with Human Hyaluronidase**  
Thursday, September 23, 12:30pm – 1:30pm, Poster Event E  
D. Muchmore, L. Morrow, M. Hompesch, E. Ludington, and D. Vaughn

**About Profil™ Institute for Clinical Research, Inc.**

Profil Institute is a privately held institute providing high quality early phase clinical research services in diabetes and obesity. To date, the company has been involved with almost every clinically promising drug and device development in diabetes and in more than 120 clinical studies since its inception in 2004. Profil Institute uses its expertise to guide the developmental planning, design and actual performance of early phase clinical studies that help in the determination of whether a new compound should be carried forward into the later phases of clinical development. The company's key scientists hail from academic centers including the WHO Collaborating Center of Diabetes at the Heinrich-Heine University of Düsseldorf, Columbia University, University of Michigan and Harvard University.

For more information visit [www.profil-research.com](http://www.profil-research.com).

For further information please contact:

Dennis DeRosia

Director Business Development

[bd@profil-research.com](mailto:bd@profil-research.com)